-
Mashup Score: 52Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard - 11 hour(s) ago
Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. They explore the use of the Decipher® genomic classifier as a prognostic and predictive tool for treatment decisions in metastatic prostate cancer. The conversation covers the test’s ability to identify patients who are likely to benefit from abiraterone and,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5
Oliver Sartor and Kambiz Rahbar discuss the RaLu study examining the safety and efficacy of sequential radiopharmaceutical treatments in metastatic castration-resistant prostate cancer. The discussion highlights how lutetium-PSMA therapy can be safely administered following radium treatment, with outcomes consistent across different treatment sequences and timing intervals. They examine how…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#RaLu Trial: Sequence of radium then lutetium in #mCRPC management. @Dr_K_Rahbar @UK_Muenster joins Oliver Sartor, MD @mayoclinic examining the safety and efficacy of sequential radiopharmaceutical treatments. #WatchNow > https://t.co/EPMMsr4r5g https://t.co/7aHLq7wZem
-
-
Mashup Score: 0Association of total testosterone levels with cardiometabolic diseases in men with erectile dysfunction. - 2 day(s) ago
Both serum testosterone (T) levels and erectile dysfunction (ED) are associated with systemic diseases in men and ED is the most common presenting symptom of hypogonadism.To evaluate the association of serum total testosterone (TT) levels with cardiometabolic diseases in men with ED.
Source: www.urotoday.comCategories: General Medicine News, Partners & KOLsTweet-
Check free T levels https://t.co/61jvqFrElk via @urotoday
-
-
Mashup Score: 22Financial Distress for GU Cancer Patients: Insights from CDC Survey - Laura Bukavina & Steven Leonard - 2 day(s) ago
Ruchika Talwar interviews Laura Bukavina and Steven Leonard about their study on financial distress for genitourinary cancer patients. Using data from the CDC National Health Interview Survey, they explore how the rising costs of cancer drugs impact patients’ financial well-being and access to care. The study reveals that GU cancer patients, particularly those with bladder and kidney cancer,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Financial distress for GU cancer patients: Insights from @CDCgov survey. @LauraBukavinaMD & Steven Leonard join @RuchikaTalwarMD to discuss how the rising costs of cancer drugs impact patients' financial well-being and access to care. Full video > https://t.co/yyexZss6I0 https://t.co/hygt4GCZuo
-
-
Mashup Score: 13ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo - 3 day(s) ago
Zach Klaassen interviews Joaquín Mateo about the ZZ-FIRST trial, which explores the combination of enzalutamide and talazoparib in metastatic hormone-naive prostate cancer. Dr. Mateo discusses the trial design, preliminary results, and the rationale behind combining AR-targeting agents with PARP inhibitors. The study shows promising results in terms of PSA complete response and early indications…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
ZZ-FIRST trial demonstrates high PSA response with combination therapy. @quimmateo @VHIO and @zklaassen_md @GACancerCenter discuss the trial design, preliminary results, and the rationale behind combining AR-targeting agents with PARP inhibitors > https://t.co/Ekd2KNBnl9 https://t.co/lEUGAEUiTf
-
-
Mashup Score: 5Medicare Part D Changes Reduce Out-of-Pocket Costs for Prostate Cancer Patients - David Morris - 3 day(s) ago
Ruchika Talwar interviews David Morris about changes to Medicare Part D resulting from the Inflation Reduction Act. Dr. Morris discusses how these changes benefit prostate cancer patients and other Medicare recipients by reducing out-of-pocket expenses for prescription drugs. Key points include the introduction of a $2,000 annual out-of-pocket maximum cap, the option for cost smoothing to spread…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#Medicare Part D changes reduce out-of-pocket costs for #ProstateCancer patients. David Morris, MD, FACS @UA_Nashville sits with @RuchikaTalwarMD @VUMCurology to discuss changes to Medicare Part D resulting from the Inflation Reduction Act > https://t.co/G6iiLFfMLV https://t.co/L6fzA11Jgo
-
-
Mashup Score: 27
Testicular Cancer, Robotic Postchemotherapy, Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND), IGCCCG classification, minimally invasive techniques for Testicular Cancer.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Oncological outcomes following robotic postchemotherapy retroperitoneal lymph node dissection for #TesticularCancer: a worldwide multicenter study. #AuthorCommentary with @alirezaghoreifi and @Hoomandjaladat. #ReadNow on UroToday > https://t.co/1wkYjkftE5 @EurUrolFocus https://t.co/oIpY5wwrpI
-
-
Mashup Score: 4Impact of ACA on Gender-Affirming Care: Urology Study Insights - Akanksha Mehta & Eric Walton - 5 day(s) ago
Ruchika Talwar interviews Eric Walton and Akanksha Metha about their study on the impact of legislation on access to gender-affirming care, published in the Gold Journal. The research examines the effects of the Affordable Care Act on insurance coverage for transgender and gender-diverse adults using the MarketScan Commercial Claims database from 2009 to 2022. The study reveals a significant…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Impact of the Affordable Care Act on gender-affirming care: Urology study insights. @akankshamehtamd and @ercwltn joins @RuchikaTalwarMD to discuss their work on the impact of legislation on access to gender-affirming care. #WatchNow on UroToday > https://t.co/EtcCyPn0Hb https://t.co/AWInna04Xs
-
-
Mashup Score: 8
Diane Newman delivers a presentation on pelvic floor muscle rehabilitation following radical prostatectomy, highlighting the prevalence and impact of post-surgical urinary incontinence. She explained that while incontinence initially affects 2-90% of patients, most improve within 2-3 months, though 5-20% may experience ongoing symptoms beyond two years. Newman emphasized the importance of pre-…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Pelvic muscle rehabilitation after radical prostatectomy. @DrDianeNewman discusses pelvic floor muscle rehabilitation following radical prostatectomy, highlighting the prevalence and impact of post-surgical urinary incontinence. #WatchNow on UroToday > https://t.co/4w1elr4CJM https://t.co/9e9jWhtp4A
-
-
Mashup Score: 9Prostate Cancer QuickTakes ESMO 2024 - ARANOTE, PEACE-3, and SPLASH Trials - Oliver Sartor - 6 day(s) ago
Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024. Dr. Sartor discusses the ARANOTE, PEACE-3, and the SPLASH trials. Biographies: Oliver Sartor, MD , Medical Oncologist, Professor of Medicine, Urology and Radiology, Director, Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Zachary Klaassen, MD, MSc , Urologic Oncologist,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#ProstateCancer #QuickTakes #ESMO24. #ARANOTE, #PEACE-3, and #SPLASH trials. Oliver Sartor, MD @MayoClinic joins @zklaassen_md @GACancerCenter to discuss on UroToday > https://t.co/0mQzpPF1k7 https://t.co/Ri8YqA4282
-
Decipher® in #mHSPC: Guiding risk assessment and treatment intensification. @AttardLab @ucl joins @Prof_Nick_James @ICR_London discussing findings from the #STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. #FullVideo on UroToday > https://t.co/rY9qSTqS13… https://t.co/GCfiSkozDB https://t.co/q3zMDsfnYz